Managers / Q4 2023 · view latest →
Propel Bio Management, LLC
CIK 0001969764 · 11620 WILSHIRE BLVD.,, SUITE 350, LOS ANGELES, CA, 90025 · 908-507-9629
Summary
Propel Bio Management, LLC reported $121M in U.S.-listed holdings across 34 positions for Q4 2023.
Its largest position, PAGP, represents 18.1% of the portfolio.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 63.1% · $76M
- Ltd Part · 18.1% · $22M
- ETP · 10.0% · $12M
- Other · 7.7% · $9M
- Closed-End Fund · 1.1% · $1M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| PAGPPLAINS GP HOLDINGS LP-CL | NEW | +1.37M | 1.37M | +$22M | $22M |
| APLTAPPLIED THERAPEUTICS INC | NEW | +5.37M | 5.37M | +$18M | $18M |
| TCRXTSCAN THERAPEUTICS INC | NEW | +2.09M | 2.09M | +$12M | $12M |
| MDGLMADRIGAL PHARMACEUTICALS INC | NEW | +30.0K | 30.0K | +$7M | $7M |
| CRNXCRINETICS PHARMACEUTICALS IN | NEW | +165.0K | 165.0K | +$6M | $6M |
| FULCFULCRUM THERAPEUTICS INC | NEW | +750.0K | 750.0K | +$5M | $5M |
| FIDELITY INV MMTRSY 1 680 | NEW | +4.77M | 4.77M | +$5M | $5M |
| PHATPHATHOM PHARMACEUTICALS INC | NEW | +443.0K | 443.0K | +$4M | $4M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2023
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $159M | 38 | May 14, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $117M | 20 | Feb 11, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $100M | 16 | Nov 12, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $82M | 16 | Aug 13, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $86M | 18 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $101M | 21 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $172M | 21 | Nov 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $154M | 25 | Aug 12, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $172M | 29 | May 13, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $121M | 34 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 1 additional manager.
- Simplify Asset Management Inc.028-20937
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.